TerminatedPhase 1NCT04525352
A Trial to Evaluate Safety and Efficacy of RP-L401-0120 in Subjects With Infantile Malignant Osteopetrosis
Studying Autosomal recessive malignant osteopetrosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Rocket Pharmaceuticals Inc.
- Principal Investigator
- Donald B Kohn, MD, MDUniversity of California, Los Angeles
- Intervention
- RP-L401(biological)
- Enrollment
- 1 enrolled
- Eligibility
- All sexes
- Timeline
- 2020 – 2021
Study locations (1)
- University of California, Los Angeles, Los Angeles, California, United States
Collaborators
California Institute for Regenerative Medicine (CIRM)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04525352 on ClinicalTrials.gov